4/A: Fennec Pharmaceuticals COO Corrects Transaction Code in Form 4 Amendment
SEC Filing Amendment
Adrian Haigh, COO of Fennec Pharmaceuticals, files an amended Form 4 to correct the transaction code for common shares acquired through option exercises under a 10b5-1 plan.
Summary
- Adrian Haigh, the Chief Operating Officer of Fennec Pharmaceuticals, filed an amendment to a previously submitted Form 4.
- The amendment corrects the transaction code for the acquisition of common shares.
- The original filing incorrectly indicated the transaction code as 'S' (sale) for the acquisition of 22,222 common shares on April 15, 2024, and another 22,222 common shares on April 16, 2024.
- The correct transaction code should have been 'M', indicating the acquisition of shares through option exercises.
- These option exercises were made pursuant to a 10b5-1 plan dated August 17, 2023.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing amendment, indicating a minor correction. It doesn't suggest any significant positive or negative implications for the company's financial health or future prospects.
Industry Context
Form 4 filings are a routine part of insider trading regulations, ensuring transparency in the market. Amendments like this are not uncommon and usually indicate a minor correction.
Key Dates
| Date | Description |
|---|---|
| 08/17/2023 | Date of the 10b5-1 plan. |
| 04/15/2024 | Date of the first transaction (acquisition of 22,222 common shares). |
| 04/16/2024 | Date of the second transaction (acquisition of 22,222 common shares) and original Form 4 filing. |
| 04/26/2024 | Date of the amended Form 4/A filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.